J&A_Midazolam_Vials.pdf

X New requirement

□ Follow on: _____________________

□ Other (specify):________________

• Proposed contract/order type.

X Firm-fixed-price

□ Other fixed-price (specify, e.g., fixed-price award-fee, fixed- price incentive-fee): Potential exists for a FPIF award

□ Cost-plus-fixed-fee

□ Other cost reimbursement (specify, e.g., cost-plus-award-fee, cost-plus-incentive-fee): _

□ Time and materials

□ Indefinite delivery (specify whether indefinite quantity, definite quantity, or requirements) : _

□ Other (specify): _

□ Completion Form □ Term form

• Acquisition identification number. AMCG-AP-2018-07 (JA-2018-02-Midazolam)

c. Total estimated dollar value and performance period. It is estimated that $700,000 will be required to support this effort. The period of performance is estimated to be a 3 month base with two one month options.

4. Identification of the statutory authority permitting other than full and open competition.

XX This acquisition is conducted under the authority of 41 United States Code (U.S.C.) 3304(a)(1) as set forth in Federal Acquisition Regulation (FAR) 6.301-1.

□ This acquisition is conducted under the authority of section 4202 of the Clinger-Cohen Act of 1996.

□ This acquisition is conducted under the authority of the Services Acquisition Reform Act of 2003 (41 U.S.C. 428a).

5. Demonstration that the proposed contractor(s) unique qualifications or the nature of the acquisition requires use of the authority cited.

a. Name and address of the proposed contractor(s).

Meridian Medical Technologies 6350 Stevens Forest Rd #301 Columbia, MD 21046

06/20/2018